

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 January 2004 (08.01.2004)

PCT

(10) International Publication Number
WO 2004/002486 A2

(51) International Patent Classification?: **A61K 31/495**

(21) International Application Number:

PCT/PH2003/000006

(22) International Filing Date: 18 June 2003 (18.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

1-2002-000485

27 June 2002 (27.06.2002) PH

(71) Applicant and

(72) Inventor: JANITZEK, Robert [DE/PH]; Bldg. 156
Bonifacio Road, SBMA, Olongapo City (PH).

(74) Agent: THE LAW FIRM OF CHAN ROBLES & AS-
SOCIATES; E-2205-B PSE Centre, Tektite East Tower,
Exchange Road, Ortigas Center, 1605 Pasig City, Metro
Manila (PH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CIPROFLOXACIN HCl

(57) **Abstract:** This invention relates to Ciprofloxacin Hydrochloride-containing composition, useful for the treatment of diseases. In particular, it relates to pharmaceutical composition comprising the following essential components: i) Ciprofloxacin Hydrochloride; ii) Magnesium stearate; iii) Starch; and iv) Carboxymethylstarch Sodium.

WO 2004/002486 A2

BEST AVAILABLE COPY